VIDEO: Targeted therapy ‘not enough’ for long-term melanoma treatment
NEW YORK — Christian Blank, MD, PhD, staff member in medical oncology and group leader of the division of immunology at Netherlands Cancer Institute, reviewed new checkpoint targets during a presentation at HemOnc Today Melanoma and Cutaneous Malignancies.
Evidence suggests checkpoint modulation will be the backbone of melanoma therapy, Blank said.
“We have treated a lot of patients with immunotherapy and we have treated a lot of patients with targeted therapy,” Blank said. “I am convinced that, for long-term benefit, we need immunotherapy.”